Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients

Phase 2 Study of Ipilimumab in Japanese Subjects With Unresectable or Metastatic Melanoma

The purpose of this study is to assess the safety of Ipilimumab monotherapy in Japanese subjects with advanced melanoma

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

• Histologically or cytologically confirmed diagnosis of malignant melanoma
• Previously-treated or untreated unresectable Stage III or Stage IV melanoma
• Measurable/evaluable disease per modified World Health Organization (mWHO) criteria, within 28 days of first dose of study drug
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Exclusion Criteria:

• Active brain metastases
• Primary ocular or mucosal melanoma
• History of or current active autoimmune disease